Compare Mutual Funds

Pros
5Y returns in the top 25% of the category.

5Y returns in the top 25% of the category.

3Y returns in the top 25% of the category.

3Y returns in the top 25% of the category.

Beats FD returns for both 3Y & 5Y duration.

Beats FD returns for both 3Y & 5Y duration.

Larger AUM within category.

Larger AUM within category.

Beats FD returns for both 3Y & 5Y duration.

Beats FD returns for both 3Y & 5Y duration.

Cons

-

5Y returns in the bottom 25% of the category.

5Y returns in the bottom 25% of the category.

3Y returns in the bottom 25% of the category.

3Y returns in the bottom 25% of the category.

INDMoney rank
4/8
8/8
Category

Equity, Sector - Healthcare

Equity, Sector - Healthcare

Fund Age

13 Years 10 Months

13 Years 10 Months

Fund AUM

₹1371 Cr

₹9279 Cr

Min Investment
  1. SIP ₹500
  2. Lumpsum ₹5000
  1. SIP ₹100
  2. Lumpsum ₹5000
Expense Ratio

1.28%

1%

Exit Load

1%

1%

Benchmark Index

BSE Healthcare TR INR

BSE Healthcare TR INR

No of Holdings

46

38

Top 5 Holdings
  1. Sun Pharmaceuticals Industries Ltd(8.71%)
  2. Divi's Laboratories Ltd(5.57%)
  3. Ajanta Pharma Ltd(4.8%)
  4. Caplin Point Laboratories Ltd(3.95%)
  5. Lupin Ltd(3.59%)
  1. Sun Pharmaceuticals Industries Ltd(13.31%)
  2. Lupin Ltd(7.25%)
  3. Divi's Laboratories Ltd(6.52%)
  4. Cipla Ltd(6.03%)
  5. Apollo Hospitals Enterprise Ltd(5.3%)
No of Sectors

1

1

Top 3 Sectors

Health

(100%)

Health

(100%)

Equity %

97.08%

97.32%

Debt %

-

-

P/E

40.78

39.56

P/B

5.72

5.84

Credit Quality

-

-

Modified Duration

-

-

YTM

-

-

1-Month Return

2.71%

1.12%

3-Month Return

13.1%

9.07%

6-Month Return

21.12%

12.24%

1-Year Return

20.05%

14.06%

3-Year Return

25.36%

19.73%

5-Year Return

16.38%

13.85%

Sharpe

1.11

0.89

Alpha

1.79

-1.2

Beta

0.96

0.88

Standard Deviation

15.93

14.77

Information Ratio

0.42

-0.87

Description

UTI Healthcare Fund is an equity fund.The fund could potentially beat inflation in the long-run.

Nippon India Pharma Fund is an equity fund.The fund could potentially beat inflation in the long-run.

Managers

Kamal Gada

Amber Singhania, Kinjal Desai, Sailesh Raj Bhan

Most Popular Comparisons